2008 Journal of Natural Products, 2007, Vol. 70, No. 12
Notes
2H), 1.47 (m, 2H); 13C NMR (CDCl3, 75 MHz) δC 174.7 (CdO ester),
154.2 (ipso C-OH), 133.3 (ipso C-alkyl), 129.5 (2 × arC), 115.3 (2 ×
arC), 72.31 (>CH-O), 72.23 (>CH-O), 51.7 (OCH3 ester), 42.5 (CH2,
C-6), 39.7 (CH2), 37.2 (CH2), 35.7 (CH2), 33.8 (CH2), 30.7 (CH2), 20.5
(CH2, C-3); ESIMS m/z 319 (M + Na)+; HRESIMS m/z 319.1514
(calcd for C16H24O5Na+, 319.1521).
APEX2 CCD area-detector diffractometer using Mo KR radiation (λ
) 0.71073 Å). Six sets of narrow data frames (60 s per frame) were
collected at different values of θ for one and five initial values of ꢁ
and ω using 0.5° increments of ꢁ or ω, respectively. Data reductions
were accomplished using SAINT V7.03.11 The substantial redundancy
(3.84) in data allowed a semiempirical absorption correction (SADABS
V2.10)11 to be applied, on the basis of multiple measurements of
equivalent reflections. The structures were solved by direct methods,
developed by successive difference Fourier syntheses, and refined by
full-matrix least-squares on all F2 data using SHELXTL V6.14.12
Hydrogen atoms were included in calculated positions and allowed
to ride on their parent atoms. Crystal data: C25H32O7S, Mw ) 476.57,
monoclinic, space group P21; dimensions: a ) 8.700(4) Å, b )
10.245(5) Å, c ) 13.949(7) Å, ꢀ ) 100.21(2)°, V ) 1223.5(10) Å3; Z
) 2; Dc ) 1.294 g cm-3; µ ) 0.174 mm-1; total reflections collected:
12 246; independent reflections: 4296 (2613Fo > 4σ(Fo)); data were
collected up to a 2θmax value of 50° (99.9% coverage), F(000) ) 508,
number of variables: 300; R1 ) 0.0732, wR2 ) 0.2069, GOF ) 0.984;
max./min., absolute structure parameter -0.04(14), residual electron
4-{(4S,6R)-6-[2-(4-Hydroxyphenyl)ethyl]-2,2-dimethyl-[1,3]dioxin-
4-yl}butyric acid methyl ester (3). To a stirred solution of 2 (27.5
mg, 0.093 mmol) in anhydrous acetone (4 mL) were added
(MeO)2CMe2 (21 mg, 0.202 mmol) and p-TsOH (4 mg). After refluxing
under nitrogen for 3 h, the solvent was eliminated under vacuum. The
residue was dissolved in CH2Cl2 (3 mL), neutralized with 2 drops of
Na2CO3 saturated solution, then dried with anhydrous MgSO4. The
organic phase was removed and the solid residue further extracted with
CH2Cl2 (3 mL). The organic phases were reassembled, then concentrated
under vacuum. A short column chromatography (Polar phase cyano-
propylsilane bonded to silica gel 40 µm, 60 Å/hexane/CH2Cl2, 3:1)
afforded 3 (26 mg, 83%) as a colorless oil: [R]25 -10.5 (c 0.80,
D
CHCl3); 1H NMR (CDCl3, 300 MHz) δH 7.03 (dt, J ) 8.2, 2.3 Hz, 2H,
meta-phenol), 6.75 (dt, J ) 8.2, 2.3 Hz, 2H, ortho-phenol), 5.29 (br s,
1H, --OH), 3.76 (m, 2H, 2 × >CH-O), 3.66 (s, 3H, OCH3 ester),
2.60 (m, 2H, CH2), 2.31 (t, J ) 7.6 Hz, CH2), 1.6–2.8 (m, 4H), 1.4–1.6
(m, 2H), 1.401 (s, 3H, isopropylydene CH3), 1.396 (s, 3H, isopropy-
lydene CH3), 1.25 (m, 2H). 13C NMR (CDCl3, 75 MHz) δC 174.2 (CdO
ester), 153.7 (ipso C-phenol), 134.0 (ipso C-alkyl), 129.6 (2 × CH
meta-phenol), 115.1 (2 × CH ortho-phenol), 98.6 (isopropylydene qC),
68.6 (>CH-O), 67.8 (>CH-O), 51.5 (ester OMe), 38.1 CH2 (ꢀ-ar CH2),
36.9 (dioxane CH2), 35.7 (γ-ester CH2), 33.8 (R-ester CH2), 30.2 (CH3
isopropylydene), 30.2 (benzylic CH2), 20.6 (ꢀ-ester CH2), 19.9 (CH3
isopropylydene); ESIMS m/z 359 (M + Na)+; HRESIMS m/z 359.1840
(calcd for C19H28O5Na+, 359.1834).
density 0.434 /-0.230 e Å-3
.
Contraction Measurement on Isolated Aortic Rings. All experi-
ments were performed on male Wistar rats (250-300 g).14,15 The
thoracic aorta of animals killed by cervical dislocation was removed
and placed into Krebs solution containing 120 mM NaCl, 4.7 mM KCl,
2.5 mM CaCl2, 1.2 mM MgCl2, 15 mM NaHCO3, 1.2 mM KH2PO4,
11 mM D-glucose, and 10 mM Hepes, pH 7.4. After separation of
connective tissues, the thoracic segment of aorta was cut into rings of
3 mm in length. The preparation was then transferred into a 5 mL organ
bath containing Krebs solution bubbled with a mixture of 95% O2 and
5% CO2. Each aortic ring was suspended between two stainless steel
hooks. One of the hooks was mounted at the bottom of the bath, whereas
the other was connected to a IT1-25 force displacement transducer
(Emka Technologies). All experiments were performed at 37 °C. A
basal tension of 2 g was applied in all experiments. During 1 h, tissues
were rinsed three times in Krebs solution, and the basal tone was always
monitored and adjusted to 2 g. Norepinephrine (10-6 M) was used to
evoke the sustained contractile response. Once the sustained tension
was established, the tissues were allowed to equilibrate further for 30
min before cumulative addition of 1 to the bath. Cumulative concen-
tration–response relationship for the relaxant effect of dodoneine was
determined in aortic rings following stable contraction. The relaxant
effect was expressed as percentage contraction of the norepinephrine-
constricted arterial rings. IC50 is the drug concentration inducing a half-
maximal vasorelaxation effect (or inhibition of contraction). Data are
presented as mean ( SE of four experiments.
(1R,5S,7S)-[2-(4-Hydroxyphenyl)ethyl]-2,6-dioxabicyclo[3.3.1]-
nonan-3-one (4). To a stirred solution of dodoneine 1 (57 mg, 0.2
mmol) in CH2Cl2 (3.5 mL) were added K2CO3 (15 mg) and water (0.5
mL), and the mixture was stirred under N2 for 6 h. The organic phase
was separated and washed with brine (2 × 1 mL), dried over MgSO4,
and evaporated under vacuum to afford a white product, which was
further crystallized from acetonitrile (47 mg, 87%): mp 170–171 °C;
[R]25D -37.5 (c 0.44, CHCl3); 1H NMR (MeOH/CDCl3 300 MHz) δH
6.99 (dt, J ) 8.5, 2.4 Hz, 2H, meta-phenol), 6.71 (dt, J ) 8.5, 2.5 Hz,
2H, ortho-phenol), 4.87 (m, 1H, >CH-O), 4.34 (br s, 1H, >CH-O),
3.65 (m, 1H, >CH-O), 2.6 (cm, 4H), 1.98 (m, 3H), 1.92 (m, 1H), 1.7
(cm, 3H); 13C NMR (MeOH/CDCl3, 75 MHz) δC 172.4 (CdO lactone),
155.9 (ipso C-OH), 133.3 (ipso C-alkyl), 130.0 (2 × CH, meta-phenol),
115.9 (2 × CH, ortho-phenol), 74.7 (>CH-O), 66.8 (>CH-O), 65.5
(>CH-O), 38.6 (CH2), 37.6 (CH2), 36.8 (CH2), 31.1 (CH2), 30.1 (CH2);
ESIMS m/z 285 (M + Na)+; HRESIMS m/z 285.1093 (calcd for
C15H18O4Na+, 285.11028).
Acknowledgment. Thanks to CNRS-France and to the University
of Poitiers-France (“Programme d’Actions Incitatives”) for financial
support. Thanks also to “Agence Universitaire de la Francophonie”
for a research grant to one of us (M.O.). Special thanks to D. Lesur
(University of Picardie, France) and to L. Lemée (UMR 6514,
University of Poitiers, France).
((S)-7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-yl)methanesulfonic acid
4-[2-((1R,3S,5S)-7-oxo-2,6-dioxabicyclo[3.3.1]non-3-yl)ethyl)phenyl es-
ter (5). To a solution of bicyclic lactone 4 (44 mg, 0.09 mmol) in
pyridine (1.5 mL) were added (1S)-(+)-10-camphorsulfonyl chloride
(205 mg, 0.8 mmol) and DMAP (5 mg) at RT. After 1 h reaction time,
CH2Cl2 (6 mL) was added, and the resulting solution was washed with
a 10% solution of NaHCO3 (3 × 5 mL). The organic phase was dried
with MgSO4 and evaporated under vacuum to afford a viscous oil.
Preparative thin-layer chromatography over silica gel (CH2Cl2/MeOH,
98:2) afforded camphorsulfonate 5 (50 mg, 68%), which was crystal-
lized from acetonitrile: mp 143–144 °C, [R]25D +12.7 (c 0.44, CHCl3);
1H NMR (CDCl3, 300 MHz) δH 7.21 (s, 4H, arH), 4.90 (br s, 1H, >CH-
O), 4.40 (br s, 1H, >CH-O), 3.77 (br s, 1H, >CH-O), 3.80 (d, J )
15.0 Hz, 1H), 3.19 (d, J ) 15.0 Hz, 1H), 2.80 (m, 3H), 2.5 (m, 3H),
References and Notes
(1) Cepleanu, F.; Hamburger, M. O.; Sordat, B.; Msonthi, J. D.; Gupta, M. P.;
Saadou, M.; Hostettman, K. Int. J. Pharmacol. 1994, 323, 294–307.
(2) Deeni, Y. Y.; Sadiq, N. M. J. Ethnopharmacol. 2002, 83, 235–240.
(3) Ouedraogo, S.; Traoré, A.; Somé, N.; Lompo, M.; Guissou, P. I.;
Schott, C.; Bucher, B.; Andriantsitohaina, R. Afr. J. Trad. Comp. Alt.
Med. 2005, 2 (1), 25–30.
(4) Ouedraogo, M.; Ouedraogo, S.; Ouedraogo, L.; Traoré, A.; Belem-
tougri, G. R.; Sawadogo, L. L.; Guissou, I. P. Afr. J. Trad. CAM 2005,
2, 166–176.
(5) Sabitha, G.; Bashkar, V.; Yadav, J. S. Tetrahedron Lett. 2006, 47,
8179–8181.
(6) Tosaki, S.-Y.; Nemoto, T.; Ohshma, T.; Shibasaki, M. Org. Lett. 2003,
5, 495–498.
(7) Sabitha, G.; Fatima, N.; Swapna, R.; Yadav, J. S. Synthesis 2006, 17,
2879–2884.
(8) Rychnovsky, S. D.; Skalitzty, D. J. Tetrahedron Lett. 1990, 31, 945–
948.
(9) Hayakawa, H.; Miyashita, M. Tetrahedron Lett. 2000, 41, 707–711.
(10) Graas, S. D.; Hunter, T. J.; O’Doherty, G. A. J. Org. Chem. 2002,
67, 2682–2685.
(11) APEX2 version 2.0–2; Bruker AXS: Madison, WI, 2003.
(12) SHELXTL version 6.14; Bruker AXS: Madison, WI, 2001.
2.0 (cm, 6H), 1.6 (cm, 5H), 1.15 (s, 3H, CH3), 0.91 (s, 3H, CH3); 13
C
NMR (CDCl3, 75 MHz) δC 214.1 (CdO ketone), 169.7 (CdO lactone),
147.4 (ipso C-OH), 140.8 (ipso C-alkyl), 129.7 (2 × CH, meta-phenol),
122.0 (2 × CH ortho-phenol), 73.0 (>CH-O), 65.9 (>CH-O), 65.0
(>CH-O), 58.1 (qC), 47.9 (qC), 47.4, 42.8 (CH), 42.4 (CH2), 37.5
(CH2), 36.9 (CH2), 36.4 (CH2), 31.0 (CH2), 29.7 (CH2), 26.8 (CH2),
25.1 (CH2), 19.9 (CH3), 19.7 (CH3).
X-ray Crystallographic Analysis of Compound 5.13 Suitable
single crystals for X-ray analyses were grown from a solution of
acetonitrile. A colorless crystal of dimensions 0.28 × 0.22 × 0.04 mm
was mounted with Araldite on a glass fiber. X-ray intensity data were
collected at room temperature, T ) 293(2) K, on a Bruker-Nonius X8-